Background: HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1-2% of lung adenocarcinomas. There is, to date, no standard of care for these patients. We thus aim to study the therapeutic outcomes of patients harboring HER2 mutations and establish the efficacy of various drug regimens.
in clinical trials. We reported in 2013 that HER2 was mutated at an incidence of 1%-2% on a series of 65 patients among which 16 were treated with anti-HER2 drugs with promising results [4] . Since this date some case reports and very few clinical trials have been reported for this population and all suggest that anti-HER2 drugs such as afatinib, dacomitinib, neratinib, and trastuzumab can be associated with tumor response [5, 6] . During the same time, large biomarker screening programs, such as the French National Program or the US Lung Cancer Mutation Consortium (LCMC), proposed systematic testing for HER2 mutations [7, 8] . We thus aimed to launch the EUHER2 cohort to provide further insights into the management of these patients by analyzing the largest cohort to date (n = 101 treated patients), particularly for the response to conventional chemotherapy and to HER2-targeted drugs. We anticipated that our findings might help to orient future clinical trials in this population.
patients and methods study design and selection of patients
This study was conducted in France, Switzerland, Spain, Italy, Poland, Portugal, and the Netherlands. Eligible patients had advanced NSCLC with an exon 20 HER2 mutation/insertion, had undergone at least one line of systemic anticancer treatment, and had received an adequate follow-up that included documented evaluation of the tumor (CT-scan every 2 or 3 months). Clinical and pathological data were collected from each patient by the treating physician. Data were de-identified at the local institution, and then collected and centralized by the study coordinator (JM) at the coordinating center in Toulouse.
Histology was assessed by experienced local pathologists using WHO criteria and the last IASLC (International Association for the Study of Lung Cancer) classification [9] . Clinico-pathological stage was assigned locally according to the 7th Tumor-Node Metastasis classification [10] . We collected clinical data, outcome variables, and the use of systemic therapies (including chemotherapy and HER2-targeted drugs) for all patients. Centers carried out follow-up CT scans at 8-12 week intervals and brain imaging in the presence of symptoms only.
Responses were defined as the best response from the start of treatment until disease progression according to response-evaluation criteria in the solid-tumor [RECIST version 1.1] guidelines. All investigators were GCP (Good Clinical Practice) certified. All tumor assessments were carried out locally: only indeterminate cases were reassessed by the coordinating center. The study was conducted with approval from the IRB at the coordinating center (14.424) and from a national ethic committee (CEPRO 2015-019).
molecular diagnostics
All participating centers had accredited and quality-controlled diagnostic laboratories that routinely tested NSCLC for EGFR, HER2, KRAS, BRAF, and ALK. Some centers also tested for ROS1, MET, and RET. For HER2 mutations, most centers carried out direct sequencing after PCR amplification of HER2 exon 20, using formalin-fixed, paraffin-embedded, and micro-dissected tumor material as previously published [4] . Some centers used nextgeneration sequencing to validate their results.
statistics
Data were summarized according to frequency and percentage for qualitative variables, and by medians and ranges for quantitative variables. Progressionfree survival (PFS) was measured as the time from the beginning of treatment to progression or death from any cause. PFS for trastuzumab and other HER2-targeted drugs was calculated from the first administration of the drug. Patients alive without progression at the time of analysis were censored at their last follow-up assessment. Survival rates were estimated according to the Kaplan-Meier method. Statistical analyses were carried out using STATA 13.0 software (StataCorp, TX, USA).
results

characteristics of the population
We identified 101 patients with an HER2 mutation who had been treated by chemotherapy and/or anti-HER2 drugs. All tumors displayed an in-frame insertion within the exon 20 of HER2-gene coding sequence. Most of the mutations were exclusive, but in seven cases (7%), there were concomitant EGFR mutations (n = 5, including one exon 19, one exon 21, two exon 20, and one exon 19 + T790M), ALK translocation (n = 1), and ROS1 (n = 1) translocation on the same analysis. The clinical characteristics of the patients are shown in Table 1 .
Our cohort was characterized by a median age of 61 years (range: 30-87), a high proportion of women (n = 63, 62.4%), and of never-smokers (n = 61, 60.4%), with a median of 15 pack-years for current and former smokers, and only four (4%) current smokers. All tumors were adenocarcinomas, including (n = 71) with pemetrexed as the preferred combination partner (n = 54); others had a doublet with bevacizumab (n = 16), a monotherapy (n = 2), or erlotinib (n = 2). In those receiving second-line therapies, RR and PFS were 10% and 4.3 months, respectively (n = 52). Most of these patients had monotherapy (15 erlotinib, 9 docetaxel, and 7 pemetrexed), fewer had a platinum-based doublet (n = 5), or a doublet with bevacizumab (n = 3). Twenty-six patients were treated with EGFR-TKI (excluding afatinib). RR with EGFR-TKI was 7.6% (one complete and one partial response), and responses were restricted to patients with a concomitant EGFR-activating mutation. Stable disease (SD) was observed in five patients (19.2%) and progressive disease (PD) in 19 patients (73.1%). The median PFS was 2.9 months (95% CI: 1.87; 4.47) ( Table 2 ). Details on all the treatment regimens are given in Table 3 .
outcome with HER2-targeted drugs
Thirty-six patients did not receive any anti-HER2 drugs, whereas 65 (64.4%) patients received at least one HER2-targeted drug, of which 47 received one line, 14 patients two lines, and 4 patients more than two lines of anti-HER2 drugs. Overall, 88 targeted treatments against HER2 were given and evaluated, including trastuzumab (n = 57), trastuzumab emtansine (T-DM1, n = 1), neratinib (n = 14), afatinib (n = 11), and lapatinib (n = 5). RR, disease control rate (DCR), and PFS were 50%, 75%, and 5.1 months, respectively, for trastuzumab in combination with chemotherapy. Chemotherapy included vinorelbine (n = 24), docetaxel (n = 12), paclitaxel (n = 12), cisplatin (n = 7), whereas two patients had trastuzumab alone. PFS and OS for patients treated with trastuzumab-based combination are shown in Figure 2 . RR, DCR, and PFS were 18.2%, 63.7%, and 3.9 months, respectively, for afatinib. Patients receiving neratinib were included in a clinical trial (PUMA-NER). Preliminary results have been reported [5] , and the final results are awaited. Lapatinib was prescribed to five patients in third-or fourth-line; all five patients had PD when the first response assessment was made. One patient had a rapid response to T-DM1, as reported elsewhere [11] . Putting together the results of trastuzumab-based treatment and T-DM1, we observed an RR of 50.9% and a PFS of 4.8 months (95% CI: 3.4; 6.5). Details concerning responses to HER2-targeting drugs are listed in Table 2 . discussion Herein, we report the largest series to date (n = 101) of patients with advanced HER2-mutant NSCLC. We confirmed the clinical characteristics of patients presenting with HER2-mutated NSCLC, as envisioned in previous series, including our own [4, [12] [13] [14] . Our patients were more often female, never-smokers, and all had adenocarcinoma histology. Looking at the natural history of HER2-mutated NSCLC, irrespective of the type of systemic therapy, we found that the median OS was ∼2 years, which was very similar to the OS observed in previous series [4, 14] . This favorable prognosis might be due to the selection of the patients (mainly women who have never smoked and patients referred to big centers with good performance status), or to a potential prognostic value of HER2 mutation. Further studies are needed to validate this hypothesis. We also analyzed the clinical outcomes of different HER2-targeted drugs. In contrast to breast cancer, the role of HER2-targeting drugs as monotherapy or in combination with chemotherapy remains unclear in lung cancer [15, 16] . Trastuzumab in combination with chemotherapy failed to show a benefit in unselected patients in a previous study [17, 18] . These early trials suggested a potential but not proven benefit for trastuzumab in patients with an overexpression or amplification of HER2. This might be due to an overlap between these patients and HER2-mutated patients. In HER2-amplified NSCLC, there was no clear clinical benefit from lapatinib [19] . Afatinib used as a monotherapy showed a response in three of three assessable patients with an HER2-mutated adenocarcinoma in an exploratory study of five patients [20] . Dacomitinib has been recently evaluated in a subpopulation of patients with an HER2 mutation or amplification in a recent trial and was associated with a low PFS (3 months) but produced undoubtedly objectives responses in three patients (12%) [21] . Similarly, no response was observed in seven patients treated with lapatinib in a large BASKET trial [22] . Neratinib has been tested in a phase II clinical trial alone and in combination with temsirolimus. When used in combination, it gave a promising RR of 21% and a PFS of 4 months [5] . As trastuzumab in our study was given concomitantly with chemotherapy, we can also anticipate that a combination of HER2-TKI and chemotherapy can lead to better results. This hypothesis should be tested in clinical trials. The European Thoracic Oncology Platform (ETOP) is currently conducting a trial (ETOP-NICHE) with afatinib in patients with advanced NSCLC and an HER2 mutation (NCT02369484). In 2006, one of us reported the seminal case of a patient with chemotherapy-refractory HER2-mutant NSCLC responding to trastuzumab in combination with paclitaxel [23] . Our previous series, which included 16 patients treated with HER2-targeted drugs, showed encouraging rates of disease control and PFS in patients who received trastuzumab after heavy pretreatment [4] . Although no dedicated trials are currently ongoing for trastuzumab therapy for HER2 mutations, our new results show an impressive RR and PFS. Thus, further prospective studies should be conducted with trastuzumab in combination with chemotherapy in patients with HER2-mutant NSCLC. T-DM1 also represents an attractive novel option, as it combines trastuzumab with chemotherapy and has given impressive results in breast cancer [24] . One patient in the EUHER2 cohort had a remarkable response to T-DM1, which has been recently published in a separate paper [11] . T-DM1 is currently being tested in a phase-II trial in patients with NSCLC and HER2 overexpression (NCT02289833). We cannot conclude about the superiority of an HER2-targeted drug from our study as the treatment has not been given at the same time of the disease and as trastuzumab is most of the time given in combination with chemotherapy, whereas HER2-TKIs are given alone.
Due to a lack of prospective data and randomized trials, it will take more years until a targeted drug can be approved for patients with HER2-mutant NSCLC. In the meantime, we hope that our data can help for the management of these patients, by showing that chemotherapy is active and should remain the basis of systemic therapy, and that trastuzumab is potentially beneficial in combination with chemotherapy. Although limited, our report suggests that small-molecule inhibitors of HER2 may be also of potential use in patients for whom no alternative treatment is available. 
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